Biosig Technologies (NASDAQ:STEX) Director Purchases $71,910.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Director Morgan Lee Lekstrom acquired 23,500 shares of Biosig Technologies stock in a transaction on Tuesday, February 3rd. The stock was purchased at an average price of $3.06 per share, with a total value of $71,910.00. Following the transaction, the director directly owned 102,500 shares in the company, valued at approximately $313,650. This trade represents a 29.75% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, January 29th, Morgan Lee Lekstrom purchased 2,500 shares of Biosig Technologies stock. The stock was acquired at an average cost of $3.70 per share, for a total transaction of $9,250.00.
• On Monday, January 26th, Morgan Lee Lekstrom acquired 23,000 shares of Biosig Technologies stock. The stock was acquired at an average price of $3.30 per share, with a total value of $75,900.00.
• On Tuesday, January 27th, Morgan Lee Lekstrom acquired 5,500 shares of Biosig Technologies stock. The shares were acquired at an average cost of $3.12 per share, with a total value of $17,160.00.
• On Friday, January 23rd, Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock. The shares were acquired at an average price of $3.13 per share, for a total transaction of $128,330.00.

Biosig Technologies Stock Down 4.5%

NASDAQ STEX opened at $2.99 on Friday. Biosig Technologies, Inc. has a twelve month low of $0.40 and a twelve month high of $14.11.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings assumed coverage on Biosig Technologies in a research report on Friday, January 23rd. They set a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.